N/A
N=38
Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients
COVID-19 Pneumonia · COVID-19 Respiratory Infection · Acute Respiratory Failure · Acute Respiratory Distress Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT04973488 ↗Enrolled (actual)
38
Serious AEs
2.6%
Results posted
Aug 2024
Primary outcome: Primary: Survival — 9; 5 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Therapeutic plasma exchange (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Novacescu Alexandru
- Primary completion
- Jan 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Survival |
9; 5 | — |
| SECONDARY P/F Ratio |
141.88; 109.61 | — |
| SECONDARY C Reactive Protein (CRP) |
46.17; 144.00 | — |
| SECONDARY Lactate Dehydrogenase (LDH) |
375.11; 548.41 | — |
| SECONDARY Ferritin |
1563.23; 1586.27 | — |
Summary
Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID-19 patients. The aim of this study is to determine whether combining TPE with convalescent plasma (CVP) transfusion early during the intensive care unit (ICU) stay, improves survival among this heterogeneous population.
Eligibility Criteria
Inclusion Criteria
- positive reverse transcriptase PCR test for COVID 19
- COVID-19 pneumonia
- All patients included were adults (>18 years)
- Acute respiratory failure
Exclusion Criteria
- pregnant women
- patients with suspected or confirmed pulmonary embolism
- patients with terminal disease
Data sourced from ClinicalTrials.gov (NCT04973488). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.